Ironwood Pharmaceuticals Non-GAAP EPS of $0.24 beats by $0.12, revenue of $122.06M beats by $46.36M [Seeking Alpha]
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ironwoodpharma.com
Company Research
Source: Seeking Alpha
Ironwood 2025 Financial Guidance. Ironwood is raising its 2025 financial guidance and now expects: Prior 2025 Guidance (August 2025) Updated 2025 Guidance (November 2025) U.S. LINZESS Net Sales $800 - $850 million $860 - $890 million Total Revenue $260 - $290 million $290 - $310 million Adjusted EBITDA $105 million $135 million Click to enlarge More on Ironwood Pharmaceuticals Ironwood wins FDA label expansion for bowel disease drug developed with AbbVie Ironwood surges 28% as beneficiary of partner AbbVie's Linzess Q3 sales Seeking Alpha's Quant Rating on Ironwood Pharmaceuticals Historical earnings data for Ironwood Pharmaceuticals Financial information for Ironwood Pharmaceuticals Recommended For You More Trending News
Show less
Read more
Impact Snapshot
Event Time:
IRWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRWD alerts
High impacting Ironwood Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
IRWD
News
- What Catalysts Are Shaping the Changing Narrative for Ironwood Pharmaceuticals? [Yahoo! Finance]Yahoo! Finance
- Ironwood Pharmaceuticals: Today's Gains Seem Sustainable After Disastrous First Half Of 2025 [Seeking Alpha]Seeking Alpha
- Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target raised by analysts at Wells Fargo & Company from $1.00 to $3.00. They now have an "equal weight" rating on the stock.MarketBeat
- Ironwood Pharmaceuticals Reports Strong Third Quarter 2025 Results; Raises Full Year 2025 Financial GuidanceBusiness Wire
- Ironwood Pharmaceuticals (NASDAQ:IRWD) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "hold" rating.MarketBeat
IRWD
Earnings
- 11/10/25 - Beat
IRWD
Sec Filings
- 11/26/25 - Form 8-K
- 11/19/25 - Form 4
- 11/14/25 - Form 144
- IRWD's page on the SEC website